Overview
Founded in 1999 by Onno van de Stolpe as a spin-out from Tibotec and Crucell, Galapagos grew into one of Belgium's most prominent biotech companies. The company is dual-listed on Euronext Brussels (part of the Bel20 index) and on Nasdaq under the ticker GLPG. Headquarters remain in Mechelen.
In 2024 and 2025 Galapagos went through a major restructuring. The company announced an exit from cell therapy operations, the closure of sites in Leiden, Basel, Princeton, Pittsburgh and Shanghai, and a workforce reduction of around 90 percent. By the end of 2026 the core team is expected to consist of 35 to 40 people across Mechelen and a US hub in Chicago. A previously announced plan to separate the company into two entities was abandoned in May 2025.
The pipeline strategy refocused on small-molecule discovery and biologics, moving away from the autologous CAR-T cell therapy programs that had defined the company in earlier years.
Listing
- Euronext Brussels: GLPG (Bel20)
- Nasdaq: GLPG
Links
- Website: https://www.glpg.com
- LinkedIn: https://linkedin.com/company/glpg
Key people
In the news
- The US Coast Guard has coordinated the rescue of 27 crew members from Ecuadorian-flagged tuna seiner Drennec, crippled by a fire on board 527 miles south-west of the Galapagos Islands. https://lnkd.in/e5n3EDvS
- Lakefront Biotherapeutics dringt operationeel verlies terug07:39 Lakefront Biotherapeutics, voorheen Galapagos, noteerde over de eerste jaarhelft een operationeel verlies van 107 miljoen euro. Dat is grosso modo een halvering ten opzichte van de eerste helft van 20...
De Tijd Farma · 11 Aug 2026
- Lakefront Biotherapeutics ziet kosten flink teruglopen(ABM FN-Dow Jones) Lakefront Biotherapeutics heeft de kosten in de eerste jaarhelft flink zien teruglopen, door onder meer de afbouw van de celtherapieactiviteiten. Dit bleek maandag nabeurs uit de resultaten van het Belgisch-Nederlandse biotechbedrijf, dat eerder bekend was als Galapagos.De R&D-kosten bedroegen in de eerste zes maanden van dit jaar 56,5 miljoen euro, vergeleken met … The post Lakefront Biotherapeutics ziet kosten flink teruglopen appeared first on Trends.be.
Trends · 10 Aug 2026
- Bestuurslid verlaat Lakefront Biotherapeutics voor Sanofi(ABM FN-Dow Jones) Paulo Fontoura legt zijn functie als lid van de Raad van Bestuur van Lakefront Biotherapeutics neer, na zijn benoeming tot Global Head of Research & Development Pharma bij het Franse Sanofi. Dit maakte het voormalige Galapagos maandagavond bekend. Fontoura wordt bij Sanofi Executive Vice President en gaat daar leiding geven aan het wereldwijde … The post Bestuurslid verlaat Lakefront Biotherapeutics voor Sanofi appeared first on Trends.be.
- We're pleased to share that today our shareholders approved our proposal to change our name to Lakefront Biotherapeutics, effective May 8th. Our new name and look and feel are designed to reflect an exciting new chapter for the Company... one in which we continue to evolve and build for the future with a clear sense of purpose and direction. Look for updates on our name change across our channels in the coming weeks! Read more: https://lnkd.in/g8zw2kCB
Open roles
- Clinical Trial ManagerMechelen · Aug 23, 2026
- Manager/Senior Manager, Corporate CommunicationsMechelen · Jul 19, 2026
- Director/Senior Director, Clinical PharmacologyJul 5, 2026
Alumni 3 went on to found or lead
David CraeyeScientist→Chief Technology Officer at Fishway- PHenry GosebruchFounding CEO XYZ SpinCo→Chief Executive Officer at Lakefront Biotherapeutics
Dries VandevyvereIT strategic projects / Head of business-wide platforms / Head of SAP→Growth & Partnerships at Eye on Data
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.